# Phytomedics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phytomedics

- Industry: Biotechnology
- Headquarters: Jamesburg, US
- Website: www.phytomedics.com
- Total disclosed funding: $17M
- Latest round: Series B (Jun 12, 2007)
- Investors on record: 2

## About

Phytomedics specializes in developing and commercializing plant-based therapeutic solutions, focusing on phytochemical compounds aimed at improving health outcomes related to inflammation, pain management, and overall wellness.Phytomedics, founded in 1996, operates from Jamesburg, US and is focused on creating innovative therapeutic products through rigorous scientific processes. The company completed two deals, with its most recent being a Series B funding round on June 12, 2007, where it raised USD 9.000 mn from Burrill & Company and Inventages Venture Capital. The company has not undergone any known pivots or changes in business operations.Phytomedics offers a range of innovative products and services primarily focused on the development and commercialization of plant-based therapeutic solutions. Their core offerings revolve around utilizing phytochemical compounds for medicinal purposes, targeting health conditions related to inflammation, pain management, and overall wellness. These products are developed through a rigorous scientific process that ensures efficacy and safety for end users, including healthcare providers and consumers seeking alternative treatment options. The company aims to serve a diverse client base, including pharmacies, health food stores, and wellness centers, catering to both retail and wholesale markets. Geographically, Phytomedics distributes its products across North America and parts of Europe, focusing on regions with a growing demand for herbal and natural remedies.Phytomedics generates revenue through a structured transaction model, engaging primarily in B2B partnerships with retailers and health practitioners. Their sales approach includes direct distribution to pharmacies and health stores, as well as potential subscription services for ongoing supply to wellness centers. The company’s flagship products are priced to reflect their premium quality and the extensive research underpinning their development. Specific pricing strategies are tailored to different customer segments, allowing flexible options for bulk purchases and retail markups. By fostering strategic partnerships within the health and wellness sector, Phytomedics positions itself for sustainable revenue growth and market expansion.Phytomedics is focusing on expanding its product line with new therapeutic solutions, although specific upcoming products and release dates have not been disclosed. The company aims to enter new markets, particularly in regions of Europe, by the end of 2023, to capitalize on the increasing demand for natural remedies. The recent Series B funding of USD 9.000 mn raised in June 2007 will be used to support these initiatives and enhance the company's capacity for product development and market entry.

## Funding rounds

- Series B, Jun 12, 2007, $9M — Burrill & Company, Inventages Venture Capital
- Series A, Jan 20, 2004, $7.5M — Burrill & Company, Inventages Venture Capital

## Investors

- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series A, Series B
- Inventages Venture Capital (https://capitalatlas.ai/funds/inventages-venture-capital) — Series A, Series B